Doravirine/lamivudine/tenofovir

Doravirine/lamivudine/tenofovir, sold under the brand name Delstrigo, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS.[3][5] It contains doravirine, lamivudine, and tenofovir disoproxil.[6][5] It is taken by mouth.[3]

Doravirine/lamivudine/tenofovir
Combination of
DoravirineNon-nucleoside reverse transcriptase inhibitor
LamivudineNucleoside reverse transcriptase inhibitor
Tenofovir disoproxilNucleotide reverse transcriptase inhibitor
Clinical data
Trade namesDelstrigo
Other namesMK-1439A
AHFS/Drugs.comMonograph
MedlinePlusa618049
License data
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Identifiers
CAS Number
KEGG

In the United States, it was approved by the Food and Drug Administration (FDA) for the treatment of HIV-1 infection in August 2018.[6][7][8]

References
  1. "PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION : DELSTRIGO" (PDF). Pdf.hres.ca. Retrieved 5 June 2022.
  2. "Delstrigo 100 mg /300 mg /245 mg film-coated tablets - Summary of Product Characteristics (SmPC)". Medicines.org.uk. 8 July 2020. Retrieved 1 October 2020.
  3. "Delstrigo- doravirine, lamivudine, and tenofovir disoproxil fumarate tablet, film coated". DailyMed. 10 October 2019. Retrieved 31 July 2020.
  4. "Delstrigo EPAR". European Medicines Agency (EMA). Retrieved 1 October 2020.
  5. Canadian Agency for Drugs and Technologies in Health (June 2019). "Common Drug Review New Combination Product: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination (Delstrigo)". CADTH Common Drug Reviews. Ottawa (ON). PMID 31393687.
  6. "FDA Approves Merck's Delstrigo (doravirine / lamivudine / tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and Pifeltro (doravirine), an NNRTI, Both for the Treatment of HIV-1 in Appropriate Patients" (Press release). Merck & Co. 30 August 2018.
  7. "Delstrigo approval letter" (PDF). Food and Drug Administration (FDA). 30 August 2018. Retrieved 10 September 2019.
  8. "Drug Approval Package: Pifeltro (doravirine)". U.S. Food and Drug Administration (FDA). 9 October 2018. Retrieved 22 September 2020.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.